Brain imaging in Alzheimer disease.

@article{Johnson2012BrainII,
  title={Brain imaging in Alzheimer disease.},
  author={Keith A. Johnson and Nick C Fox and Reisa A. Sperling and William E. Klunk},
  journal={Cold Spring Harbor perspectives in medicine},
  year={2012},
  volume={2 4},
  pages={
          a006213
        }
}
Imaging has played a variety of roles in the study of Alzheimer disease (AD) over the past four decades. Initially, computed tomography (CT) and then magnetic resonance imaging (MRI) were used diagnostically to rule out other causes of dementia. More recently, a variety of imaging modalities including structural and functional MRI and positron emission tomography (PET) studies of cerebral metabolism with fluoro-deoxy-d-glucose (FDG) and amyloid tracers such as Pittsburgh Compound-B (PiB) have… 

Figures from this paper

Quantitative multimodal multiparametric imaging in Alzheimer’s disease
TLDR
This review provides a preliminary summary of the various neuroimaging techniques that have been explored for in vivo imaging of AD, and expects exciting results will emerge from new neuroim imaging applications that will provide scientific and medical benefits.
Optimizing Use of Neuroimaging Tools in Evaluation of Prodromal Alzheimer's Disease and Related Disorders.
TLDR
The work describes state of the art functional and molecular imaging methods for AD and overviews a clinically applicable quantitative method for reproducible assessments of such scans in the early identification of AD.
Biomarkers for Alzheimer’s Disease Early Diagnosis
TLDR
Several potential markers in the brain, eye, blood, and other accessible biofluids like saliva and urine are summarized and discussed to correlate them with earlier diagnosis and prognosis to identify individuals with mild symptoms prior to dementia.
Amyloid imaging in Alzheimer’s disease: a potential new era of personalized medicine?
TLDR
Personalized medicine has now emerged as a prospect for the field, but the recent decision by the Centers for Medicare & Medicaid Services — who declined to cover the cost of amyloid PET imaging citing insufficient evidence to support its clinical utility — highlights that such a move may be premature.
Functional MRI technologies in the study of medication treatment effect on Alzheimer's disease
TLDR
Noninvasive in vivo functional magnetic resonance imaging technologies used to study the effect of ChEIs and memantine in the brain support the understanding of the mechanisms underlying the medication treatments and support the crucial role of functional MRI technologies in the development and refinement of AD medication therapies.
Amyloid PET imaging: applications beyond Alzheimer’s disease
TLDR
The potential use of amyloid PET tracer accumulation in cerebral white matter (WM) as a marker of myelin is being investigated, leading to some promising results in patients with WM lesions and multiple sclerosis.
Multimodal neuroimaging on neurodegenerative disorders using the hybrid PET/MRI technique
TLDR
The data suggest that combination of intrinsic functional connectivity, glucose metabolism, and grey matter volume based on network degeneration hypothesis can serve as a valid biomarker to separate patients with distinct neurodegenerative disorders.
...
...

References

SHOWING 1-10 OF 249 REFERENCES
The clinical use of structural MRI in Alzheimer disease
TLDR
The utility of structural imaging and other markers will be increased by standardization of acquisition and analysis methods, and by development of robust algorithms for automated assessment, as well as by research into other imaging and nonimaging markers.
FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease.
TLDR
Visual interpretation of FDG-PET after brief training is more reliable and accurate in distinguishing FTD from AD than clinical methods alone and adds important information that appropriately increases diagnostic confidence, even among experienced dementia specialists.
Relative capability of MR imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease.
TLDR
The current results show no evidence that FDG PET is more sensitive than MR imaging to the degeneration occurring in preclinical and mild AD, suggesting that an MR imaging finding may be a more practical clinical biomarker for early detection of AD.
FDG PET imaging in patients with pathologically verified dementia.
TLDR
This study confirms that bilateral temporo-parietal hypometabolism is indeed the classic metabolic abnormality associated with AD and the sensitivity, specificity, and diagnostic accuracy of FDG PET are acceptable as tests to be used in the evaluation of dementia and particularly to confirm the clinical suspicion of AD.
PET imaging of amyloid deposition in patients with mild cognitive impairment
In vivo amyloid imaging with PET in frontotemporal dementia
TLDR
PIB could potentially aid in differentiating between FTD and AD, and eight FTD patients showed significantly lower PIB retention compared to AD in frontal, parietal, temporal, temporal and occipital cortices.
Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer’s disease
Serial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer's disease
...
...